AAAAAA

   
Results: 1-10 |
Results: 10
FEASIBILITY TRIAL OF PACLITAXEL (PXL), OXALIPLATIN (L-OHP) AND CISPLATIN (CDDP) COMBINATION IN ADVANCED OVARIAN-CANCER PATIENTS
Authors: CHOUAKI N TAAMMA A LADEM A DELALOGE S MISSET JL PAUTIER P LHOMME C CVITKOVIC E
Citation: N. Chouaki et al., FEASIBILITY TRIAL OF PACLITAXEL (PXL), OXALIPLATIN (L-OHP) AND CISPLATIN (CDDP) COMBINATION IN ADVANCED OVARIAN-CANCER PATIENTS, Annals of oncology, 9, 1998, pp. 346-346
ECTEINASCIDIN-743 (ET-743) 24 HOURS CONTINUOUS-INFUSION (CI) - CLINICAL AND PHARMACOKINETIC PHASE-I STUDY PROGRESSIVE REPORT
Authors: RIOFRIO M TAAMMA A MCKRANTER B GOLDWASSER F JIMENO J JASMIN C MISSET JL CVITKOVIC E
Citation: M. Riofrio et al., ECTEINASCIDIN-743 (ET-743) 24 HOURS CONTINUOUS-INFUSION (CI) - CLINICAL AND PHARMACOKINETIC PHASE-I STUDY PROGRESSIVE REPORT, Annals of oncology, 9, 1998, pp. 639-639
ECTEINASCIDIN-743 (ET-743) 24-HOUR CONTINUOUS INTRAVENOUS-INFUSION (CI) PHASE-I STUDY IN SOLID TUMORS (ST) PATIENTS
Authors: CVITKOVIC E MEKRANTER B TAAMMA A GOLDWASSER F BEIJNEN JH JIMENO J RIOFRIO M VEGA E MISSET JL HOP P
Citation: E. Cvitkovic et al., ECTEINASCIDIN-743 (ET-743) 24-HOUR CONTINUOUS INTRAVENOUS-INFUSION (CI) PHASE-I STUDY IN SOLID TUMORS (ST) PATIENTS, Annals of oncology, 9, 1998, pp. 456-456
OXALIPLATIN - A REVIEW OF PRECLINICAL AND CLINICAL-STUDIES
Authors: RAYMOND E CHANEY SG TAAMMA A CVITKOVIC E
Citation: E. Raymond et al., OXALIPLATIN - A REVIEW OF PRECLINICAL AND CLINICAL-STUDIES, Annals of oncology, 9(10), 1998, pp. 1053-1071
PALLIATIVE TREATMENT WITH LOW-DOSE CONTINUOUS-INFUSION 5-FLUOROURACILIN RECURRENT AND OR METASTATIC UNDIFFERENTIATED NASOPHARYNGEAL CARCINOMA TYPE/
Authors: FANDI A TAAMMA A AZLI N BACHOUCHI M YANES B ARMAND JP CVITKOVIC E
Citation: A. Fandi et al., PALLIATIVE TREATMENT WITH LOW-DOSE CONTINUOUS-INFUSION 5-FLUOROURACILIN RECURRENT AND OR METASTATIC UNDIFFERENTIATED NASOPHARYNGEAL CARCINOMA TYPE/, Head & neck, 19(1), 1997, pp. 41-47
PHASE-I CLINICAL-STUDY OF ECTEINASCIDIN-743 (ET-743) AS A 24 HOURS CONTINUOUS INTRAVENOUS-INFUSION (CI) IN PATIENTS (PTS) WITH SOLID TUMORS(ST) - A PROGRESS REPORT
Authors: TAAMMA A CVITKOVIC E JIMENO J GASPARETTO M MEELEY K VEGA E CAMERON L MISSET JL
Citation: A. Taamma et al., PHASE-I CLINICAL-STUDY OF ECTEINASCIDIN-743 (ET-743) AS A 24 HOURS CONTINUOUS INTRAVENOUS-INFUSION (CI) IN PATIENTS (PTS) WITH SOLID TUMORS(ST) - A PROGRESS REPORT, European journal of cancer, 33, 1997, pp. 1119-1119
SCHEDULE-DEPENDENT PACLITAXEL TOLERANCE ACTIVITY - DATA FROM A 7 DAY INFUSION PHASE-I STUDY WITH PHARMACOKINETICS IN PACLITAXEL REFRACTORY OVARIAN-CANCER/
Authors: SOULIE P TRANDAFIR L TAAMMA A LOKIEC F BRAIN E DELORD JP MITA A VANNETZEL JM CVITKOVIC E MISSET JL
Citation: P. Soulie et al., SCHEDULE-DEPENDENT PACLITAXEL TOLERANCE ACTIVITY - DATA FROM A 7 DAY INFUSION PHASE-I STUDY WITH PHARMACOKINETICS IN PACLITAXEL REFRACTORY OVARIAN-CANCER/, Anti-cancer drugs, 8(8), 1997, pp. 763-766
PRELIMINARY-RESULTS OF A RANDOMIZED TRIAL COMPARING NEOADJUVANT CHEMOTHERAPY (CISPLATIN, EPIRUBICIN, BLEOMYCIN) PLUS RADIOTHERAPY VS RADIOTHERAPY ALONE IN STAGE-IV (GREATER-THAN-OR-EQUAL-TO-N2, M0) UNDIFFERENTIATED NASOPHARYNGEAL CARCINOMA - A POSITIVE EFFECT ON PROGRESSION-FREESURVIVAL
Authors: CVITKOVIC E ESCHWEGE F RAHAL M",DOSEN,"MERSIC Z KRAJINA Z ARMAND JP BOUHRIS J TUBIANAMATHIEU M FOUNTZILAS G KOSMIDIS PA PRASAD U GANESAN S ELGUEDDARI B BACHOUCHI M MANSOURI A OLIVEIRA J RAPOSO J WIERZBICKI R LIANES P PENA C ONAT H ALTUN M BENHAMOU E DUCOURTIEUX M AZLI N FANDI A TAAMMA A BOSQ J KLIJANIENKO J SIGAL R HONG WK VOKES EE CLARK JR LEFLOCH O BERNIER J
Citation: E. Cvitkovic et al., PRELIMINARY-RESULTS OF A RANDOMIZED TRIAL COMPARING NEOADJUVANT CHEMOTHERAPY (CISPLATIN, EPIRUBICIN, BLEOMYCIN) PLUS RADIOTHERAPY VS RADIOTHERAPY ALONE IN STAGE-IV (GREATER-THAN-OR-EQUAL-TO-N2, M0) UNDIFFERENTIATED NASOPHARYNGEAL CARCINOMA - A POSITIVE EFFECT ON PROGRESSION-FREESURVIVAL, International journal of radiation oncology, biology, physics, 35(3), 1996, pp. 463-469
5-FLUOROURACIL (FU) BLEOMYCIN (B), EPIRUBICIN (E), CISPLATIN (P) IN LOCALLY ADVANCED (LA), RECURRENT AND OR IMETASTATIC (REC/MTS) UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE (UNCT) PRELIMINARY ACTIVITY TOXICITY REPORT/
Authors: FANDI A TAAMMA A AZLI N BACHOUCHI M YANES B CVITKOVIC E ARMAND J
Citation: A. Fandi et al., 5-FLUOROURACIL (FU) BLEOMYCIN (B), EPIRUBICIN (E), CISPLATIN (P) IN LOCALLY ADVANCED (LA), RECURRENT AND OR IMETASTATIC (REC/MTS) UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE (UNCT) PRELIMINARY ACTIVITY TOXICITY REPORT/, European journal of cancer, 31A, 1995, pp. 401-401
UNDIFFERENTIATED CARCINOMA OF THE NASOPHA RYNX - EPIDEMIOLOGIC, CLINICAL AND THERAPEUTIC ASPECTS
Authors: FANDI A YANES B TAAMMA A AZLI N ARMAND JP DUPUIS O ESCHWEGE F SCHWAAB G CVITKOVIC E
Citation: A. Fandi et al., UNDIFFERENTIATED CARCINOMA OF THE NASOPHA RYNX - EPIDEMIOLOGIC, CLINICAL AND THERAPEUTIC ASPECTS, Bulletin du cancer, 81(7), 1994, pp. 571-586
Risultati: 1-10 |